Eli Lilly and Company (NYSE:LLY) Trading Down 1.3% - Time to Sell?

Key Points

• Eli Lilly's stock price fell by 1.3% on Monday, trading as low as $701.50, with a significant drop in trading volume, down 82% from the average.
• Several analysts adjusted their target prices, with Deutsche Bank lowering theirs from $1,010.00 to $900.00, while the consensus target price remains at $950.17.
• Eli Lilly recently declared a quarterly dividend of $1.50 per share, with a current dividend yield of 0.9% and a payout ratio of 39.22%.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price was down 1.3% on Monday . The stock traded as low as $701.50 and last traded at $702.08. Approximately 764,148 shares were traded during trading, a decline of 82% from the average daily volume of 4,147,917 shares. The stock had previously closed at $711.68.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Guggenheim dropped their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Trading Down 1.9%

The stock has a market capitalization of $660.67 billion, a PE ratio of 45.60, a P/E/G ratio of 0.99 and a beta of 0.44. The company's 50 day moving average price is $754.70 and its two-hundred day moving average price is $789.97. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Insider Activity

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently made changes to their positions in the stock. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the 1st quarter valued at about $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $27,000. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth $31,000. Finally, Bare Financial Services Inc increased its holdings in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company's stock valued at $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.